Objective: To investigate the efficacy and safety of topiramate in obese subjects with type 2 diabetes treated with metformin. Design: This was a multicenter, double-blind, placebo-controlled trial. All subjects received a non-pharmacological program of diet, exercise and behavioral modification throughout the study; the assigned diet was 600 kcal/day less than the subject's individually calculated energy expenditure. After a 6-week single-blind placebo run-in, subjects were randomized to placebo, topiramate 96 mg/day or topiramate 192 mg/day. Following an 8-week titration period, subjects remained on their assigned dose for 52 weeks. However, the sponsor ended the study early in order to develop a new controlled-release formulation with the potential to enhance tolerability and simplify dosing in this patient population. A total of 646 obese men and women (age: 18-75 years, body mass index: 27-50 kg/m 2 ) with an established history of type 2 diabetes mellitus controlled by metformin monotherapy were randomized. Efficacy was assessed in a pre-determined modified intent-to-treat (MITT) population of 307 subjects whose randomization date would have allowed them to complete 24 weeks on study medication before the announcement of study termination. Measurements: Joint primary efficacy parameters were mean percent change in weight and change in glycosylated hemoglobin (HbA 1c ) from baseline to week 24. Results: Subjects in the placebo, topiramate 96 mg/day and topiramate 192 mg/day groups lost 1.7%, 4.5% (Po0.001) and 6.5% (Po0.001), respectively, of their baseline body weight and had absolute decreases in HbA 1c of 0.1%, 0.4% (Po0.001) and 0.6% (Po0.001) (MITT, last observation carried forward). Topiramate-treated subjects also experienced statistically significant decreases in systolic blood pressure. Most common adverse events were paresthesia and events related to the central nervous system. Conclusions: Topiramate was effective for weight reduction and improvement in glycemic control in obese subjects with type 2 diabetes treated with metformin monotherapy. Further study in obese diabetics is warranted.
Introduction
Several studies have demonstrated that excess weight is a major risk factor for diabetes in both men 1 and women, 2, 3 as well as in the adult population as a whole. 4 Even modest weight loss has been shown to significantly reduce the risk of progression from pre-diabetes to diabetes 5, 6 and to lead to better glycemic control, 7 as well as improvements in cardiovascular risk factors such as hypertension 8, 9 and dyslipidemia. 10, 11 Diabetes is itself a major risk factor for hypertension, dyslipidemia and cardiovascular disease, with approximately 65% of diabetes patients dying of cardiovascular or cerebrovascular causes. 12 Current American Diabetes Association (ADA) standards of care give aggressive control of glycemia the same emphasis as control of hypertension and dyslipidemia. 13 The importance of the standard initial treatment for both obesity and diabetes -lifestyle modification including diet and exercise -has recently been reviewed by the ADA. 14 However, the generally disappointing long-term results of these treatment modalities have led to increased interest in pharmaceutical intervention. Effective medications for maintaining glycemic control in diabetic patients are available. One of the most frequently prescribed in obese diabetic subjects is metformin as, unlike insulin, sulfonylureas or thiazolidinediones, it does not promote weight gain, [15] [16] [17] and further pharmacological weight-loss options are clearly needed. 18 Topiramate, a sulfamate-substituted monosaccharide that is approved worldwide for the adjunctive treatment of specific seizure disorders and for migraine prophylaxis, has been investigated for the treatment of obesity and type 2 diabetes. Topiramate has shown dose-related weight loss in rodent models of obesity and diabetes. 19, 20 A 6-month dose-ranging study in humans likewise found dose-related weight loss. 21 In a study of longer duration, weight loss continued for at least 1 year. 22 In a weight-loss maintenance study, 23 randomized subjects who had lost at least 8% of their enrollment weight during an 8-week low-calorie-diet run-in were given placebo or topiramate. In the topiramatetreated subjects, weight loss continued for 44 weeks, with evidence of stability for 16 weeks thereafter. By contrast, placebo-treated subjects experienced weight regain after week 24.
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The present study was carried out to investigate the efficacy and safety of topiramate for weight loss in a population of obese individuals with type 2 diabetes being treated with metformin. Efficacy was evaluated in terms of both weight loss and glycemic parameters.
Materials and methods

Study design and recruitment
This randomized, double-blind, placebo-controlled, parallelgroup study recruited subjects at 68 centers in Canada, Europe and South Africa and was performed from 11 October 2000 to 14 June 2002. The study was originally planned for 72 weeks, consisting of a 6-week placebo run-in phase followed by randomization, an 8-week titration phase, a 52-week maintenance phase, a 2-week taper and a 4-week follow-up phase. However, the topiramate immediate-release clinical program in obesity and diabetes was discontinued in order to develop a new controlled-release formulation with the potential to enhance tolerability and simplify dosing in this patient population, and the current study was ended early (On December 1, 2004, Johnson and Johnson Pharmaceutical Research & Development LLC announced discontinuation of the current clinical development program for its controlled-release formulation of topiramate in obesity and type 2 diabetes. Data from a completed phase II clinical study with the controlled-release formulation of topiramate showed that this formulation did not provide significant advantages in this population compared to previously conducted studies using the immediate-release formulation.).
Subjects conforming to the following criteria were eligible for enrollment: aged 18-75 years, body mass index (BMI) X27 and o50 kg/m 2 , established history of type 2 diabetes mellitus, glycosylated hemoglobin (HbA 1c ) o11%, and fasting plasma glucose (FPG) between 7 and 13 mmol/l (126 and 240 mg/dl). Subjects were required to have been on metformin monotherapy for at least 4 months with a stable dose for at least 2 months. A previously completed healthy volunteer drug-drug interaction study revealed that the addition of topiramate to steady-state metformin resulted in a decrease in metformin clearance of approximately 20%. The clinical significance of this effect is not known; however, in the current study, the metformin total daily dose was not to exceed 2.1 g/day. An established diagnosis of hypertension or dyslipidemia was allowed, provided the dose of antihypertensive and/or hypolipidemic medication had been stable for at least 2 months; the dose was to be maintained for the duration of the study. Female subjects of childbearing potential were required to use an approved method of birth control. Subjects with a history of central nervous system (CNS)-related or psychiatric disorders, conditions likely to affect weight or clinically significant renal/hepatic disease were excluded, as were those using psychotropic medication or medication influencing weight. Subjects who lost at least 6% of their initial body weight on non-pharmacologic therapy during the placebo run-in period were excluded from randomization.
The study was designed and conducted in accordance with the Declaration of Helsinki and ICH Good Clinical Practice Guidelines and was approved by Ethics Committees at all study sites. All subjects provided written informed consent before enrollment.
Pathways to Change s
All subjects participated in a non-pharmacologic lifestyle intervention program, Pathways to Change (Johnson & Johnson Healthcare Systems, Inc., Piscataway, NJ, USA), from enrollment and throughout the full duration of the study. The focus of the program was on diet, exercise and self-management strategies delivered by counselors who worked one-on-one with subjects. The lesson plans were different at each visit but consistent across all study sites. The energy level of the prescribed diabetic diet was 600 kcal less than the individual subject's calculated total energy expenditure and was recalculated at week 32.
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Topiramate in obese type 2 diabetics on metformin H Toplak et al Randomization, titration and maintenance After the 6-week placebo run-in, subjects were randomized to receive placebo, topiramate 96 mg/day or topiramate 192 mg/day (divided doses b.i.d.), with randomization by permuted blocks stratified by study site.
The 8-week titration phase began with administration of 16 mg topiramate once daily to subjects assigned to one of the two topiramate groups. In the second week, topiramate was administered at 16 mg twice daily (32 mg/day). The dose was thereafter increased each week by 32 mg/day until the assigned dose was reached (on week 4 for the 96 mg/day group and on week 7 for the 192 mg/day group). During the maintenance phase, the dose remained constant (placebo, 96 or 192 mg/day, divided doses b.i.d.). Study drug was tapered by approximately 50% per week over a 2-week period upon study completion or early withdrawal. The final follow-up visit was 4 weeks later.
Dose reductions
A single, double-blind dose reduction of topiramate was allowed in the event of intolerable adverse events. Subjects randomized to 192 mg/day were reassigned to 96 mg/day, those randomized to 96 mg/day were reassigned to 64 mg/ day and those on placebo were reassigned to receive placebo. Subjects were to be withdrawn if the intolerable adverse event persisted. All subjects were analyzed in their originally targeted randomized dose, regardless of subsequent adjustment.
In the presence of severe and/or recurrent hypoglycemia, investigators had the option to reduce the dose of metformin on one occasion. Persistence of hypoglycemia following metformin dose reduction necessitated withdrawal of the subject. All subjects received home glucose monitoring meters and diaries to record potential hypoglycemic events.
Efficacy assessments
As the study was terminated early by the sponsor, efficacy data are based on a modified-intent-to-treat (MITT) population consisting of all randomized subjects who had the opportunity to complete at least 24 weeks of double-blind treatment before the decision to stop the study early was made. This MITT population was pre-defined before unblinding and data analysis. Joint primary end points were mean percent change from baseline to week 24 in body weight and absolute change in HbA 1c . Secondary efficacy criteria included: mean changes in FPG; changes in metformin dose; mean changes in HbA 1c for subjects who had HbA 1c X7 or X8% at randomization (baseline, week 0); number of subjects with X5 and X10% decrease in body weight (5, and 10% weight loss responders); mean changes in lipids, mean changes in blood pressure and mean changes in blood pressure for subjects with baseline systolic blood pressure X140 mm Hg or baseline diastolic blood pressure X90 mm Hg. Other secondary end points were mean percent changes in body weight over time and mean changes in HbA 1c over time, using all non-missing observations. Fasting insulin levels were not measured within the reported 24-week period.
Safety evaluations
Safety was assessed in all subjects who received at least one dose of study medication and provided any on-treatment safety data. Safety assessments were based on reported adverse events by non-direct questioning, hypoglycemic events, clinical laboratory values, vital sign measurements, physical examination and electrocardiographic measurements.
Statistical analysis
This study had joint primary end points, mean percent weight change and mean change in HbA 1c . The end points were analyzed in the MITT population using the last observation carried forward (LOCF) technique by analysis of covariance with treatment, center and gender as factors; baseline values and change in body weight during placebo run-in were covariates. Since both end points were correlated, the significance level was adjusted using Dubey's method to reflect the observed degree of correlation. 25 Quantitative secondary end points were similarly analyzed using the MITT LOCF population. Response rates and other categorical variables were analyzed using the CochranMantel-Haenzel test or Fisher's exact test. All MITT subjects were included in the analysis.
Results
Study population
A total of 646 subjects were randomized at the end of the 6-week run-in phase; 640 subjects were included in the safety population and 307 in the MITT population ( Figure 1 ). Demographic characteristics of the safety population are shown in Table 1 . The demographic characteristics of the MITT population were similar to those of the safety population.
The baseline HbA 1c (7.1%) and FPG (8.7 mmol/l) of subjects in the safety population indicated these subjects were well controlled at baseline. Mean weight loss during the placebo run-in phase was approximately 1% across treatment groups.
The number of subjects in the MITT population achieving target dose was 87 (87%), 89 (87%) and 83 (79%) in the placebo, topiramate 96 and 192 mg/day groups, respectively. The number of subjects completing 4 months of maintenance therapy at the target dose was 77 (77%), 77 (75%) and 67 (64%) in the placebo, topiramate 96 mg/day and topiramate 192 mg/day groups, respectively. The average total actual daily dose of topiramate in the MITT population Beginning at week 4 and at each 4-week time point thereafter, weight loss was significantly greater in each topiramate group than in the placebo group (Figure 2 , MITT all observed data at all time points). The plot of weight loss vs time for the subset of the MITT population who were 24-week completers is virtually identical to Figure 2 . Topiramate (Table 2 ). In contrast, HbA 1c levels in the placebo group showed little change from baseline.
At week 24, the proportion of subjects losing at least 5% and 10% of their baseline body weight was significantly greater in the topiramate 96 and 192 mg/day groups than in the placebo group (Figure 3) . Additionally, the proportion of subjects having at least a 0.5%, 0.7% or 1.0% decrease in HbA 1c was 36% (Po0.05), 21% and 16% (Po0.02) in the 96 mg/day group, and it was 48% (Po0.001), 37% (Po0.001) and 17% (Po0.01) in the 192 mg/day group compared with 23%, 12% and 5% in the placebo group. All P-values compare treatment groups vs placebo.
In the subgroup of subjects who had baseline HbA 1c X7% (n ¼ 59, 49 and 51 for the placebo, topiramate 96 mg/day and topiramate 192 mg/day groups, respectively), the decreases were 0.1% for the placebo group, compared with 0.6% for topiramate 96 mg/day and 0.8% for the topiramate 192 mg/ day group (Pp0.003). In the small number of subjects with baseline HbA 1c X8% (n ¼ 19, 20 and 19 for the placebo, 96 and 192 mg/day groups, respectively), the decreases for the three groups were 0.2, 1.0 and 0.9%, respectively (Po0.05 vs placebo for both of the topiramate groups).
From baseline to week 24, FPG increased by less than 0.1 mmol/l in the placebo group and decreased by 0.6 mmol/ l in the topiramate 96 mg/day group, and by 1.1 mmol/l in the topiramate 192 mg/day group (Pp0.001 vs placebo for both treatment groups) ( Table 2) .
In this predominantly normotensive study population, diastolic blood pressure increased by 0.1 mm Hg in placebotreated subjects, compared with decreases of 1.8 and 1.7 mm Hg in the two topiramate groups (P ¼ NS). For systolic blood pressure, the mean changes in the three groups were À0.8, À5.3 and À4.9 mm Hg, respectively (Po0.01 vs placebo for both treatment groups) ( Table 2 ). 
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At baseline, subjects had borderline normal lipid values, and no clinically relevant changes in lipid profile at week 20 were observed (Table 2 ). Thirty-three of 100 (33%), 19/102 (19%) and 25/105 (24%) of subjects in the placebo, topiramate 96 mg/day and topiramate 192 mg/day groups (MITT Population), respectively were on lipid-lowering medication at baseline. No patients in any group had a dose reduction of these concomitant medications.
Safety
Safety data are reported for all subjects who received at least one dose of study medication with at least one post-dose safety assessment. The incidence of study drug dose reductions for intolerable adverse events was 2%, 10% and 20% for placebo, topiramate 96 mg/day and topiramate 192 mg/day, respectively. Table 3 represents adverse events occurring in at least 5% of topiramate-treated subjects and at a greater incidence than in subjects receiving placebo. Adverse events of interest that occurred more frequently in topiramate-treated subjects than in the placebo group were generally related to the central/peripheral nervous system, were psychiatric in nature, or included fatigue. Paresthesia occurred in 32% of topiramate-treated subjects and was most likely due to the known carbonic anhydrase inhibitory effect of topiramate.
The incidence of withdrawal from the study for adverse events was 7%, 9% and 18% for placebo, topiramate 96 mg/ day and topiramate 192 mg/day, respectively. Adverse events leading to withdrawal from the study in at least 2% of Table 3 Common treatment-emergent adverse events (safety population) Events seen in at least 5% of topiramate-treated subjects and more common than in placebo subjects.
Topiramate in obese type 2 diabetics on metformin H Toplak et al topiramate-treated subjects are listed in Table 4 . Three percent of topiramate-treated subjects withdrew from the study because of paresthesia. The incidence of hypoglycemic reaction (symptoms of hypoglycemia for which no confirmatory low blood glucose value was available) was similar for topiramate (6%) vs placebo (5%). Hypoglycemia, confirmed by a low blood glucose measurement, occurred in 3% on topiramate treatment vs 1% on placebo. These events were reported as mild to moderate in severity; no severe hypoglycemic events were reported, and no subject was withdrawn from the study because of hypoglycemia.
The mean dose of metformin during the study was 1360 mg/day. Metformin was discontinued in two placebotreated subjects and in two topiramate-treated subjects. The incidence of dose reductions was 2% in the placebo group vs 6% in the topiramate groups, and the incidence of dose increases was 4 vs 1% for the placebo and topiramate groups, respectively.
Serious adverse events were observed in 7% of topiramatetreated subjects and 4% of placebo-treated subjects. The most common serious adverse event was injury, experienced by six subjects (1%) in the combined topiramate groups; these were mostly sprains and fractures, not or doubtfully related to study drug. Injuries were not related to hypoglycemia, nor were they associated with significant CNS-related adverse events. Two subjects experienced serious adverse events possibly related to study drug; these included increased hepatic enzymes and alkaline phosphatase in one patient and fever, diarrhea, viral infection, leukopenia, hemorrhage, hepatic failure and acute renal failure in the other. The latter patient, a 42-year-old woman in the 192 mg/ day group, died of hemorrhage secondary to hepatic failure on day 39 of the study. Multiple confounding factors and potential alternative etiologies were noted. The subject's illness began with fever and sore throat, consistent with viral infection, and the subject progressed to multi-organ failure and died within 15 days of the onset of symptoms. An autopsy revealed evidence of pre-existing liver disease but no evidence of a toxic reaction.
Serum bicarbonate decreased in topiramate-treated subjects (2.92 and 3.37 mmol/l in the 96 and 192 mg/day topiramate groups, vs 0.71 mmol/l for placebo), which was not unexpected in view of the compound's known activity as a carbonic anhydrase inhibitor. These decreases were accompanied by compensatory increases in chloride levels. There were no reported cases of clinically manifest metabolic acidosis. There were no other clinically significant changes in laboratory parameters.
Discussion
Full interpretation of the currently reported data and comparison with the literature is impaired by the fact that the study was terminated early and that efficacy data are presented for a 6-month treatment period only. Still, weight loss at week 24 was significantly greater in each topiramate group than in the placebo group. Similarly, there was a statistically significant improvement in HbA 1c for the topiramate 96 mg/day and topiramate 192 mg/day groups vs placebo. Although these reductions in HbA 1c were modest, baseline (after the 6-week run-in phase) HbA 1c values were barely above the ADA target treatment goal of p7%. Consequently, in the subsets of subjects with worse glycemic control at baseline (HbA 1c X7 or X8%), decreases in HbA 1c were more pronounced.
The weight changes seen in the current study are clinically relevant. Even modest weight reductions in patients with type 2 diabetes can lead to improved glycemic control. 7 Weight loss may also produce improvements in cardiovascular risk factors such as hypertension 8, 9 and dyslipide- Adverse events leading to discontinuation in X2% topiramate-treated subjects.
Topiramate in obese type 2 diabetics on metformin H Toplak et al important for obese individuals with diabetes than for those without the disease, some studies suggest that it may also be more difficult. 27, 28 Thus, pharmacological support for weight loss may be particularly appropriate in the diabetic population. Subjects were predominantly normotensive and normolipidemic at baseline. This may account for the relatively modest changes in blood pressure and lipid profile, although topiramate effects on systolic blood pressure were statistically significant.
The mechanism through which topiramate facilitates weight loss has not been fully elucidated but is apparently different from that of either sibutramine or orlistat. Sibutramine is a combined norepinephrine/serotonin reuptake inhibitor. It produces more rapid satiation and may also enhance thermogenesis. 29 Orlistat is an inhibitor of gastric and pancreatic lipases that partially blocks digestion of dietary fat. As a result, the recipient's actual caloric absorption is less than that normally produced by a given food intake. 29 Topiramate does not act through noradrenergic or serotonergic mechanisms. It is known to modulate effects at the g-aminobutyric acid (GABA-A) receptor 30 and at glutamate receptors of the a-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA)/kainate subtype 31 in addition to producing state-dependent blockade of voltage-dependent Na þ or Ca 2 þ channels. 32 However, the relationship of these actions to its anti-obesity effects remains unclear.
In animal models of obesity, topiramate has consistently reduced the efficiency of energy utilization. Reductions in food consumption were seen in some models but not in others; however, an effect on food intake in humans cannot be excluded. 19, 20 Effects on energy utilization may be modulated through tissue-selective increases in expression of uncoupling proteins 2 and 3, 33 as well as through increased thermogenesis resulting from stimulation of lipoprotein lipase in brown fat and skeletal muscle. 19, 20 Although vital sign measurements and clinical observations in this and other studies of topiramate have provided no indication of increased thermogenesis in man, possible increases too small to be readily apparent cannot be ruled out. Over a period of months, such small increases could account for the observed weight loss. 34 A potential effect of topiramate on food intake warrants further investigation. In summary, this study found topiramate added to metformin to be efficacious for weight loss in obese subjects with type 2 diabetes mellitus. Although most subjects were already in good glycemic control at baseline, a further reduction in HbA 1c among topiramatetreated subjects was observed. Thirty-two percent of subjects reported paresthesia, but only 3% discontinued as a result; other common adverse effects were related to the central nervous system or were psychiatric in nature. Further study of topiramate in diabetic subjects is warranted.
